Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.36 |
| ▸ | DBH | P09172 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 3/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | GRK2 | P25098 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914668 | 0.94 | ACLY (0.40) | CYP11B1CYP11B2ACLYCYP17A1CYP3A4 | |
| SCHEMBL3915034 | 0.89 | CYP11B1 (0.42) | MEN1KMT2ACYP11B1CYP11B2ACLY | |
| SCHEMBL3911329 | 0.86 | CYP11B1 (0.46) | MEN1KMT2ACYP11B1CYP11B2ACLY | |
| SCHEMBL3112868 | 0.85 | VEGFA (0.44) | MEN1KMT2ACYP11B1CYP11B2ACLY | |
| SCHEMBL3923792 | 0.85 | SMN1; SMN2 (0.41) | CYP11B1CYP11B2ACLYCYP17A1CYP3A4 | |
| SCHEMBL3913436 | 0.84 | HSP90AA1 (0.44) | CYP11B1CYP11B2CYP17A1CYP3A4CYP19A1 | |
| SCHEMBL3913221 | 0.84 | ESRRG (0.40) | CYP11B1CYP11B2ACLYCYP17A1CYP3A4 | |
| SCHEMBL3913855 | 0.83 | FNTA (0.41) | CYP11B1CYP11B2ACLYCYP17A1CYP3A4 | |
| SCHEMBL3920808 | 0.83 | SMN1; SMN2 (0.43) | MEN1KMT2ACYP11B1CYP11B2CYP3A4 | |
| SCHEMBL3924211 | 0.82 | EGLN1 (0.51) | MEN1KMT2AACLYLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | MEN1 853/4885KMT2A 3205/4885CYP11B1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.